Gaja Andzel
Endocrinology, Diabetes & Metabolism · Yucaipa, CANPI 1821231648
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,160 of the $111,142 with a category attached, or 78.4%. Corcept Therapeutics accounts for 75.8% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $28,805, more than ten times the $1,618 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $259.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$84K
- Mannkind Corporation$11K
- Abbott$9K
- Novo Nordisk$3K
- AstraZeneca$522
- Amgen$399
- plus $2K from 27 others
What the payments were for
- Consulting fees$8,7408%
- Speaking & faculty fees$87,16078%
- Travel & lodging$5,4055%
- Food & beverage$9,1788%
- Education$5400%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 129 | $84,212 |
| Mannkind Corporation | 56 | $11,390 |
| Abbott | 20 | $9,015 |
| Novo Nordisk | 67 | $3,139 |
| AstraZeneca | 24 | $522 |
| Amgen(2 entities) | 17 | $399 |
| Lilly USA, LLC | 12 | $335 |
| Sanofi-aventis U.S. LLC | 15 | $303 |
| Amarin Pharma, Inc. | 17 | $280 |
| Endo Pharmaceuticals Inc. | 8 | $135 |
| Xeris Pharmaceuticals, Inc. | 6 | $131 |
| Insulet Corporation | 6 | $127 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Sanofi | 1 | $105 |
| Merck | 6 | $101 |
| Companion Medical, Inc. | 4 | $97 |
| Tandem Diabetes Care, Inc. | 4 | $93 |
| Radius Health, Inc. | 3 | $73 |
| Lifescan, Inc. | 4 | $72 |
| Therapeuticsmd, Inc. | 3 | $64 |
| IBSA Pharma Inc. | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| AbbVie | 3 | $48 |
| Dexcom, Inc. | 3 | $47 |
| Bayer | 2 | $45 |
| Boehringer Ingelheim | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Johnson & Johnson | 2 | $32 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$82,089
- AFREZZA$10,648
- FreeStyle Libre 2$7,402
- FreeStyle Libre Pro$1,500
- ZENPEP$125
- Wegovy$125
- TEPEZZA$122
- SOLIQUA 100/33$105
How this compares
$111,142 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 40 | $51,460 |
| ProgesteroneProgesterone, Micronized | 49 | $2,580 |
| Celecoxib | 12 | $1,426 |
| Liothyronine Sodium | 17 | $891 |
| Testosterone Cypionate | 12 | $440 |
| Levothyroxine Sodium | 21 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $335 | $51,46040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Yucaipa
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.